We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
New River Pharmaceuticals has filed its new drug application (NDA) for NRP104, developed as an abuse-resistant follow-on drug to Shire Pharmaceuticals' attention-deficit/hyperactivity disorder (ADHD) drug Adderall XR.
The FTC has filed an amicus brief asking a federal appeals court to rehear a case against AstraZeneca and Barr Laboratories that charged that the drugmakers violated antitrust laws with their patent settlement over AstraZeneca's breast cancer drug Nolvadex.
Roche has pared a list of 200 potential Tamiflu partners down to 12 with whom it plans to begin "in-depth" negotiations for sub-licensing agreements for the highly sought-after antiviral.
Roche has pared a list of 200 potential Tamiflu partners down to 12 with whom it plans to begin “in-depth” negotiations for sub-licensing agreements for the highly sought-after antiviral.
Roche will soon announce licensing agreements with 15 pharmaceutical companies and governments, enabling the organizations to manufacture Tamiflu, the antiviral being stockpiled in the event of a flu pandemic, government officials said.
Bristol-Myers Squibb (BMS) inked a pair of collaboration agreements this week — one focused on developing novel cardiovascular disease treatments and the other on domain antibody products.
Indian drugmaker Dr. Reddy’s has expanded its presence in North America, agreeing to purchase Roche’s active pharmaceutical ingredient (API) business in Mexico.